36
views
0
recommends
+1 Recommend
0
shares
    • Review: found
    Is Open Access

    Review of 'Drug repositioning framework driven by landscape analysis and competitive intelligence: A case report on Prader Willi Syndrome'

    Bookmark
    2
    Drug repositioning framework driven by landscape analysis and competitive intelligence: A case report on Prader Willi SyndromeCrossref
    Key informations are missing, even for a review contribution
    Average rating:
        Rated 2 of 5.
    Level of importance:
        Rated 2 of 5.
    Level of validity:
        Rated 2 of 5.
    Level of completeness:
        Rated 2 of 5.
    Level of comprehensibility:
        Rated 2 of 5.
    Competing interests:
    None

    Reviewed article

    • Record: found
    • Abstract: found
    • Conference Proceedings: found
    Is Open Access

    Drug repositioning framework driven by landscape analysis and competitive intelligence: A case report on Prader Willi Syndrome

    Drug repositioning is a promising strategy to develop therapeutics for rare diseases 1,2. In our present work, we explore a drug repositioning framework that can capture the clinical unmet needs of Prader Willi syndrome (PWS) showing ineffectiveness of GLP1 agonists 3, widely accepted as the standard of care for lifestyle obesity. Several therapeutic axes have been explored against PWS such as enzyme replacement therapy 4,5, Ghrelin analogues 6, MC4R agonist 7, however none of these approaches have shown preventive action, thus leaving a wide scope for exploring drug repositioning in PWS. Market share analysis of GLP1 agonists used against PWS along with the overall market size and growth of obesity medication shows the room for market penetrance in rare conditions of genetic obesity. Novo Nordisk and Eli Lilly dominate the obesity therapeutics market with their blockbuster drugs like Ozempic, Wegovy 8, Trulicity and most recently Zepbound 9. In addition, entry of Zealand Pharmaceuticals and Viking Therapeutics are set to provide additional therapeutic options to patients of obesity 10,11. However, the competitive landscape surrounding PWS therapies points to a significant gap, as genetic obesity has potential multi-systemic involvement and not only the metabolic axis 12. This framework provides life cycle management opportunities in other genetic obesity conditions such as Bardet-Biedl syndrome (BBS), Kleefstra syndrome- EHMT1 mutation, Alstrom syndrome, Biemond syndrome type 2, Wolfram syndrome, Cohen syndrome, familial isolated DCM and mitochondrial disorders 13.
      Bookmark

      Review information

      Review text

      Could I suggest you expand on your rather short abstract by first describing the complexity of PWS, e.g., the lack of Gonadotropin-Releasing Hormone (GnRH) release in the hypothalamus or the missing SNORD116? Current therapy. Unmet need. The review of the GLP1 agonists should be enriched with clinical or experimental data. Currently, it sounds more like an idea. 

      Comments

      Comment on this review